Actually, AML including t‐AML patients who are not eligible for IC are treated by combinations of HMA or cytarabine with Bcl2 inhibitors with or without targeted therapies (FLT3 inhibitors, IDH1 and 2 inhibitors, and anti‐CD47 antibody).19, 51, 52. Here, IDH1 is linked to acute myeloid leukemia.